-
1 Comment
Celldex Therapeutics, Inc is currently in a long term uptrend where the price is trading 27.3% above its 200 day moving average.
From a valuation standpoint, the stock is 93.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 81.3.
Celldex Therapeutics, Inc's total revenue rose by 326.7% to $4M since the same quarter in the previous year.
Its net income has dropped by 109.6% to $-22M since the same quarter in the previous year.
Finally, its free cash flow grew by 50.9% to $-5M since the same quarter in the previous year.
Based on the above factors, Celldex Therapeutics, Inc gets an overall score of 4/5.
| CurrencyCode | EUR |
|---|---|
| Industry | Biotechnology |
| Sector | Healthcare |
| ISIN | US15117B2025 |
| Exchange | F |
| Target Price | 64.83 |
|---|---|
| Beta | 2.17 |
| PE Ratio | None |
| Market Cap | 1B |
| Dividend Yield | 0.0% |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TCE2.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
